SCHEMBL13178686

SCHEMBL13178686

CCC(CC)c1cc2ccccc2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.51
ALDH1A1 P00352 3/20 0.51
MAPT P10636 1/20 0.51
BRD4 O60885 1/20 0.47
ALOX5 P09917 1/20 0.46
LOXL2 Q9Y4K0 1/20 0.44
AOC3 Q16853 2/20 0.44
DAO P14920 1/20 0.43
DDO Q99489 1/20 0.43
TSHR P16473 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
DRD2 P14416 1/20 0.41
HPGD P15428 2/20 0.41
CHEK1 O14757 1/20 0.41
KDR P35968 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
FLT3 P36888 1/20 0.40
CYP2A6 P11509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22931232 0.90 DRD2 (0.47) KDM4EALDH1A1MAPTBRD4ALOX5
SCHEMBL22931310 0.85 DRD2 (0.49) KDM4EALDH1A1MAPTBRD4ALOX5
SCHEMBL7814836 0.85 ALOX5 (0.50) KDM4EALDH1A1MAPTBRD4ALOX5
SCHEMBL9227391 0.84 KDM4E (0.42) KDM4EALDH1A1MAPTALOX5LOXL2
SCHEMBL31497395 0.84 ALOX5 (0.48) KDM4EALDH1A1MAPTALOX5DAO
SCHEMBL8298140 0.83 ALOX5 (0.49) KDM4EALDH1A1MAPTBRD4ALOX5
SCHEMBL26012345 0.83 ALOX5 (0.49) KDM4EALDH1A1MAPTBRD4ALOX5
SCHEMBL27372960 0.82 KDM4E (0.43) KDM4EALDH1A1MAPTBRD4ALOX5
SCHEMBL29875124 0.81 ALOX5 (0.48) KDM4EALDH1A1MAPTBRD4ALOX5
SCHEMBL3034192 0.81 KDM4E (0.49) KDM4EALDH1A1MAPTBRD4ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230030414-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2023-02-02 US disclosed
EP-4059932-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2022-09-21 EP disclosed
EP-3354650-B1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMA (US) 2022-02-16 EP disclosed
US-10961232-B2 Substituted pyrazines as ATR kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-03-30 US disclosed
US-10479784-B2 Substituted pyrazin-2-amines as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-11-19 US disclosed
US-20190047995-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2019-02-14 US disclosed
US-20180170922-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2018-06-21 US disclosed
US-9701674-B2 Substituted pyrazines as ATR kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10961232-B2 Substituted pyrazines as ATR kinase inhibitors ATR, MAP3K5, CHEK1 KDM4E 1741/4885ALDH1A1 3775/4885MAPT 3129/4885
US-20190047995-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 KDM4E 2108/4885ALDH1A1 3961/4885MAPT 2916/4885
US-20230030414-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 KDM4E 2108/4885ALDH1A1 3961/4885MAPT 2916/4885
US-10479784-B2 Substituted pyrazin-2-amines as inhibitors of ATR kinase ATR, CHEK2, CHEK1 KDM4E 1289/4885ALDH1A1 3704/4885MAPT 2663/4885
US-20180170922-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 KDM4E 2108/4885ALDH1A1 3961/4885MAPT 2916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.